SCHEMBL237634

SCHEMBL237634

Cc1nc2cc(C3CC3)nn2c(N)c1C=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.37
RAB9A P51151 5/20 0.37
PIK3CG P48736 1/20 0.35
SMN1; SMN2 Q16637 5/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 4/20 0.33
NFKB1 P19838 1/20 0.33
HTT P42858 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
KDM4E B2RXH2 4/20 0.32
PDE10A Q9Y233 1/20 0.32
MAPT P10636 2/20 0.31
LMNA P02545 2/20 0.31
TP53 P04637 2/20 0.31
MEN1 O00255 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
PKM P14618 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL236642 0.81 KDM4E (0.47) NPC1RAB9APIK3CGSMN1; SMN2ALDH1A1
SCHEMBL239828 0.76 NPC1 (0.37) NPC1RAB9APIK3CGSMN1; SMN2ALDH1A1
SCHEMBL238224 0.73 PLAT (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL237815 0.72 FYN (0.35) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL239684 0.69 NPC1 (0.34) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL236943 0.68 KDR (0.40) NPC1RAB9APDE10A
SCHEMBL5052666 0.68 MAPT (0.42) NPC1RAB9APIK3CGSMN1; SMN2ALDH1A1
SCHEMBL5056012 0.68 RAB9A (0.44) NPC1RAB9APIK3CGSMN1; SMN2ALDH1A1
SCHEMBL237593 0.66 FYN (0.39) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL1019767 0.65 PIK3CG (0.33) NPC1RAB9APIK3CGSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885PIK3CG 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.